Risk of SGLT2 inhibitor‐associated diabetic ketoacidosis in type 2 diabetes: some answers, but more questions
Prescribers have enthusiastically embraced sodium–glucose cotransporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes on the strength of accumulating data reporting improved cardiovascular and renal outcomes. In Australia, in 2016, 757 826 Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescriptions containing an SGLT2 inhibitor were dispensed. By 2019, that number had risen to 2.3 million.1 Assuming these scripts are dispensed monthly, an estimated 19% of all patients with type 2 diabetes (about 190 000 people) are currently being treated with SGLT2 inhibitors.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.